Bo Heng Zhang

Summary

Affiliation: Zhongshan Hospital
Country: China

Publications

  1. ncbi Randomized controlled trial of screening for hepatocellular carcinoma
    Bo Heng Zhang
    Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai 200032, China
    J Cancer Res Clin Oncol 130:417-22. 2004
  2. doi [Effect of postoperative adjuvant transarterial chemoembolization on late recurrence of hepatocellular carcinoma after radical resection]
    Xiao hong Chen
    Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai 200032, China
    Zhonghua Gan Zang Bing Za Zhi 18:599-603. 2010
  3. ncbi [Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma]
    Yu hong Gan
    Department of, Liver Cancer Institute, Fudan University, Shanghai 200032, China
    Zhonghua Zhong Liu Za Zhi 26:496-8. 2004
  4. ncbi The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma
    Hui Zhang
    Liver Cancer Institute and Zhongshan Hospital, Institutes of Biomedical Science, Fudan University, 180 Feng Lin Road, Shanghai, 200032, China
    J Cancer Res Clin Oncol 132:709-17. 2006
  5. ncbi [Effect of postoperative transcatheter arterial chemoembolization on hepatocellular carcinoma patients with residual tumor]
    Zheng gang Ren
    Liver Cancer Intitute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    Zhonghua Zhong Liu Za Zhi 26:116-8. 2004
  6. ncbi The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma
    Ning Ren
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, China
    J Cancer Res Clin Oncol 132:399-407. 2006
  7. pmc Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria
    Lan Zhang
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Xue Yuan Road, Shanghai 20032, China
    BMC Gastroenterol 14:11. 2014
  8. ncbi [The value of CA19-9 in diagnosing hepatocellular carcinoma and intrahepatic cholangiocarcinoma]
    Yi Chen
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China
    Zhonghua Gan Zang Bing Za Zhi 14:299-300. 2006
  9. ncbi [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]
    Lan Zhang
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
    Zhonghua Zhong Liu Za Zhi 32:630-3. 2010
  10. ncbi [Cryohepatectomy for liver cancer: preliminary evaluation of reducing postoperative recurrence]
    Xin Da Zhou
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    Zhonghua Wai Ke Za Zhi 43:439-41. 2005

Collaborators

Detail Information

Publications21

  1. ncbi Randomized controlled trial of screening for hepatocellular carcinoma
    Bo Heng Zhang
    Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai 200032, China
    J Cancer Res Clin Oncol 130:417-22. 2004
    ..The aim of this study was to assess the effect of screening on HCC mortality in people at increased risk...
  2. doi [Effect of postoperative adjuvant transarterial chemoembolization on late recurrence of hepatocellular carcinoma after radical resection]
    Xiao hong Chen
    Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai 200032, China
    Zhonghua Gan Zang Bing Za Zhi 18:599-603. 2010
    ..To identify the effect of postoperative adjuvant transarterial chemoembolization (TACE) on late recurrence of hepatocellular carcinoma (HCC) patients after radical resection...
  3. ncbi [Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma]
    Yu hong Gan
    Department of, Liver Cancer Institute, Fudan University, Shanghai 200032, China
    Zhonghua Zhong Liu Za Zhi 26:496-8. 2004
    ..To study the clinical safety and effect on local recurrence in unresectable small hepatocellular carcinoma treated by radiofrequency ablation (RFA) with and without chemotherapy through a prospective randomized trial...
  4. ncbi The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma
    Hui Zhang
    Liver Cancer Institute and Zhongshan Hospital, Institutes of Biomedical Science, Fudan University, 180 Feng Lin Road, Shanghai, 200032, China
    J Cancer Res Clin Oncol 132:709-17. 2006
    ..This suggests that the preoperative plasma OPN level can be used as a predictive marker for HCC recurrence and may be helpful to assess the prognosis of patients with HCC after surgery...
  5. ncbi [Effect of postoperative transcatheter arterial chemoembolization on hepatocellular carcinoma patients with residual tumor]
    Zheng gang Ren
    Liver Cancer Intitute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    Zhonghua Zhong Liu Za Zhi 26:116-8. 2004
    ..To evaluate the effect of postoperative adjuvant transcatheter arterial chemoembolization (TACE) on hepatocellular carcinoma (HCC) patients with residual tumor...
  6. ncbi The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma
    Ning Ren
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, China
    J Cancer Res Clin Oncol 132:399-407. 2006
    ..This study assesses the value of circulating plasma DNA level and its allelic imbalance (AI) on chromosome 8p in the prediction of HCC prognosis...
  7. pmc Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria
    Lan Zhang
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Xue Yuan Road, Shanghai 20032, China
    BMC Gastroenterol 14:11. 2014
    ..The purpose of this study was to evaluate the effectiveness and safety of radiofrequency ablation following first-line TACE treatment in the management of HCC beyond the Milan Criteria...
  8. ncbi [The value of CA19-9 in diagnosing hepatocellular carcinoma and intrahepatic cholangiocarcinoma]
    Yi Chen
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China
    Zhonghua Gan Zang Bing Za Zhi 14:299-300. 2006
  9. ncbi [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]
    Lan Zhang
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
    Zhonghua Zhong Liu Za Zhi 32:630-3. 2010
    ..To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC)...
  10. ncbi [Cryohepatectomy for liver cancer: preliminary evaluation of reducing postoperative recurrence]
    Xin Da Zhou
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    Zhonghua Wai Ke Za Zhi 43:439-41. 2005
    ..To determine whether cryohepatectomy is potentially beneficial in reducing the recurrence and prolonging survival for hepatocellular carcinoma (HCC)...
  11. ncbi Coexpression of stemness factors Oct4 and Nanog predict liver resection
    Xin Yin
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, Chinese Ministry of Education, Shanghai, China
    Ann Surg Oncol 19:2877-87. 2012
    ..The aim of this study was to evaluate the correlation between these two stemness markers with recurrence, metastasis, and prognosis of hepatocellular carcinoma (HCC)...
  12. ncbi [Effect of postoperative adjuvant transarterial chemoembolization upon early recurrence after radical resection of hepatocellular carcinoma]
    Xiao hong Chen
    Department of Liver Medical Oncology, Liver Cancer Institute, Zhongshan Hospital of Fudan University, Shanghai 200032, China
    Zhonghua Yi Xue Za Zhi 90:826-9. 2010
    ..To explore the effect of postoperative adjuvant transarterial chemoembolization (TACE) upon early recurrence of hepatocellular carcinoma (HCC) patients after radical resection...
  13. pmc Decreased expression of GATA2 promoted proliferation, migration and invasion of HepG2 in vitro and correlated with poor prognosis of hepatocellular carcinoma
    Yi Wei Li
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion Fudan University, Ministry of Education, Shanghai, China
    PLoS ONE 9:e87505. 2014
    ..However, their expression patterns and prognostic values for hepatocellular carcinoma (HCC) are still largely unknown...
  14. pmc Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis
    Tong chun Xue
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, PR China
    BMC Gastroenterol 13:60. 2013
    ..This meta-analysis evaluated the efficacy and safety of TACE for treatment of HCC with PVTT...
  15. doi [Role of chemokine CCL28 in hypoxia-induced migration of hepatocellular carcinoma]
    Ying Zhou
    Liver Cancer Institute of Zhongshan Hospital, Fudan University, Shanghai 200032, China
    Zhonghua Gan Zang Bing Za Zhi 21:524-7. 2013
    ..To investigate the role of CCL28 in hypoxia-induced cell migration of hepatocellular carcinoma (HCC)...
  16. ncbi Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma
    Hui Chuan Sun
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China
    J Hepatol 47:684-90. 2007
    ..To study the impact of hepatitis B e antigen on tumor recurrence and patients' survival after curative resection of hepatocellular carcinoma...
  17. pmc Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation
    Jian He
    Department of Radiation Oncology, Fudan University, Shanghai, China
    BMC Cancer 11:492. 2011
    ..Little is known about the clinical features and prognostic factors of bone metastases of hepatocellular carcinoma (HCC) following liver transplantation (LT)...
  18. ncbi P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma
    Yong Bing Qian
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
    Cancer 107:1562-9. 2006
    ..The identification of predictive markers of outcome will help to select patients who are most likely to benefit from treatment...
  19. ncbi Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients
    Ning Ren
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
    World J Gastroenterol 12:3911-4. 2006
    ..To quantify the circulating DNA in plasma from patients with hepatocellular carcinoma (HCC) and to evaluate its prognostic value...
  20. ncbi Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial
    Hui Chuan Sun
    Liver Cancer Institute and Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, 200032, Shanghai, People s Republic of China
    J Cancer Res Clin Oncol 132:458-65. 2006
    ..This study evaluated the effect of postoperative interferon alpha (IFN alpha) treatment on recurrence and survival in patients with hepatitis B virus (HBV)-related HCC...
  21. ncbi Surgery for large primary liver cancer more than 10 cm in diameter
    Xin Da Zhou
    The Liver Cancer Institute, Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, 200032, Shanghai, China
    J Cancer Res Clin Oncol 129:543-8. 2003
    ..Large primary liver cancer (PLC) more than 10 cm in diameter is not infrequently encountered in clinical practice. This study evaluated the clinicopathological features and long-term results after surgery for large PLC...